Folfiri as Third Line of Treatment
NCT03486379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26
Last updated 2018-04-03
Summary
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
Conditions
- Gastric Cancer
- Ramucirumab
- Third Line
Sponsors & Collaborators
-
IRCCS Cancer Referral Center of Basilicata
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2017-09-30
- Completion
- 2018-03-23
More Related Trials
-
Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer
NCT06365008 ·Status: RECRUITING ·Phase: PHASE2
-
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
NCT03647969 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel and Irinotecan in Advanced Gastric Cancer
NCT01136031 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer
NCT00611507 ·Status: COMPLETED ·Phase: PHASE2
-
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
NCT03045770 ·Status: UNKNOWN ·Phase: NA
-
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
NCT00343668 ·Status: UNKNOWN ·Phase: PHASE2
-
Feasibility of a Molecular Characterisation Approach to Treatment
NCT02112357 ·Status: UNKNOWN
-
POF Versus FOLFOX Plus IP Paclitaxel in AGC
NCT04155671 ·Status: UNKNOWN ·Phase: PHASE2
-
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
NCT03044587 ·Status: COMPLETED ·Phase: PHASE2
-
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
NCT02845908 ·Status: COMPLETED ·Phase: PHASE2
-
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
NCT06871527 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
NCT05643677 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
NCT01746771 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
NCT06666582 ·Status: COMPLETED
-
FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
NCT03283761 ·Status: COMPLETED ·Phase: PHASE2
-
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
NCT07309185 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
NCT02114359 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
NCT03646591 ·Status: COMPLETED
-
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
NCT02934464 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
NCT01123876 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
NCT03684811 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT01896531 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
NCT02209441 ·Status: AVAILABLE
-
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611 ·Status: RECRUITING ·Phase: PHASE2
-
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
NCT03137004 ·Status: UNKNOWN ·Phase: PHASE2